Naproxen sodium/sumatriptan - Old API Wind-down
Alternative Names: MT-400; Naproxen sodium/sumatriptan succinate; SumaRT/Nap; Sumatriptan/naproxen sodium; Suvexx; Trexima; TreximetLatest Information Update: 05 Nov 2023
At a glance
- Originator GlaxoSmithKline; POZEN
- Developer Currax Pharmaceuticals; Miravo Healthcare; Old API Wind-down Ltd
- Class Anti-inflammatories; Antimigraines; Indoles; Naphthaleneacetic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Sulfonamides; Tryptamines
- Mechanism of Action 5-HT1 serotonin receptor agonists; Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Migraine
Most Recent Events
- 15 Aug 2023 Launched for Migraine in Estonia, Lithuania, Latvia, Hungary, Poland, Norway, Denmark, Sweden, Finland (PO)
- 15 Aug 2023 Naproxen sodium/sumatriptan licensed to Orion for the exclusive right to package, distribute, market and sell, in all remaining European Union countries outside of the original License Agreement Territory
- 15 Aug 2023 Orion announces intention to launch Naproxen sodium/sumatriptan for Migrain in Austria, Belgium, the Czech Republic, France, Germany, Greece, Ireland, Italy, the Netherlands, Portugal, Slovakia, Spain, Switzerland and the UK